Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPOND: Infliximab + MTX vs MTX in PsA
NCT00367237Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2006
- Primary completion
- Mar 2008
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of infliximab in psoriatic arthritis (PsA), sponsored by Merck & Co.. Started May 2006; status: completed.
02
Drugs
infliximab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT00367237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00367237.